Brokers Offer Predictions for NeuroPace, Inc.’s Q3 2024 Earnings (NASDAQ:NPCE)

NeuroPace, Inc. (NASDAQ:NPCE) – Research analysts at Leerink Partnrs raised their Q3 2024 earnings estimates for shares of NeuroPace in a research note issued on Tuesday, August 13th. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings per share of ($0.26) for the quarter, up from their prior forecast of ($0.30). The consensus estimate for NeuroPace’s current full-year earnings is ($1.14) per share. Leerink Partnrs also issued estimates for NeuroPace’s Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($1.10) EPS, Q1 2025 earnings at ($0.28) EPS, Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($1.00) EPS, FY2026 earnings at ($0.77) EPS, FY2027 earnings at ($0.51) EPS and FY2028 earnings at $0.01 EPS.

Several other research analysts also recently commented on the stock. Wells Fargo & Company decreased their target price on shares of NeuroPace from $20.00 to $15.00 and set an “overweight” rating on the stock in a research note on Wednesday. Morgan Stanley lowered their price objective on shares of NeuroPace from $9.50 to $8.00 and set an “equal weight” rating for the company in a research note on Monday, July 15th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $18.00 target price on shares of NeuroPace in a research note on Wednesday. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $14.00.

NeuroPace Stock Performance

Shares of NPCE stock opened at $6.87 on Friday. The company has a market capitalization of $197.64 million, a P/E ratio of -5.77 and a beta of 1.80. NeuroPace has a fifty-two week low of $4.21 and a fifty-two week high of $18.15. The company has a debt-to-equity ratio of 4.05, a quick ratio of 5.56 and a current ratio of 6.43. The stock has a 50 day moving average price of $7.16 and a two-hundred day moving average price of $10.83.

NeuroPace (NASDAQ:NPCE) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.03. The firm had revenue of $19.26 million for the quarter, compared to the consensus estimate of $18.30 million. NeuroPace had a negative return on equity of 173.62% and a negative net margin of 45.61%. The company’s quarterly revenue was up 16.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.36) earnings per share.

Institutional Investors Weigh In On NeuroPace

Several institutional investors and hedge funds have recently modified their holdings of NPCE. Millennium Management LLC increased its position in shares of NeuroPace by 13.3% during the second quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock valued at $5,186,000 after buying an additional 80,324 shares during the period. Vanguard Group Inc. grew its holdings in shares of NeuroPace by 18.3% during the 1st quarter. Vanguard Group Inc. now owns 488,618 shares of the company’s stock worth $6,450,000 after acquiring an additional 75,512 shares during the period. Acadian Asset Management LLC bought a new position in shares of NeuroPace in the 1st quarter worth approximately $621,000. Bank of New York Mellon Corp purchased a new position in shares of NeuroPace in the 2nd quarter valued at approximately $257,000. Finally, Rhumbline Advisers bought a new stake in shares of NeuroPace during the second quarter valued at approximately $111,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.